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The first report of an association between chronic infection with
Helicobacter pylori, a spiral bacterium of the stomach, and gastric
cancer appeared in 1991 and in 1994 the International Agency for
Research of Cancer declared H. pylori a human ‘carcinogen’
(IARC Working Group, 1994). Five years after that report,
however, the causal role of H. pylori in gastric cancer remains
controversial, with risk estimates ranging from ninefold (Webb
and Forman, 1996) to no important association at all (Crespi and
Citarda, 1996). Recent quantitative reviews, by contrast, suggest
that H. pylori infection is likely to be only a moderate risk factor
for gastric cancer (Danesh, 1999a, 1999b).
Reliable epidemiological evidence on H. pylori and gastric
cancer is still relatively sparse. Although the number of cases
reported in prospective studies has increased by threefold since
1994, there are now a total of only about 800 cases in ten published
prospective studies. A synthesis of these studies indicates that H.
pylori is two or three times more common in people with gastric
cancer than in others (Figure 1). Doubts persist, however, about the
extent to which inadequate adjustment for possible confounding
factors, such as smoking and markers of poverty, and the preferen-
tial publication of studies with more extreme results might have led
to exaggerated estimates. The biological plausibility of a causal
association is suggested by strong correlations reported between H.
pylori infection and putatively precancerous gastric lesions (such as
atrophic gastritis and intestinal metaplasia) (Kuipers et al, 1995;
Sakaki et al, 1995) and by the production of lesions that resemble
human gastric cancer in Mongolian gerbils following long-term
experimental infection (Watanabe et al, 1998). Even if a two- or
threefold relative risk were established, however, it would not
explain the sharp variations in gastric cancer mortality between
populations (e.g. 20-fold higher in certain parts of China than in the
USA) (Peto, 1990) or between past and present (e.g. the fivefold
decrease in Scotland between 1950 and 1990) (Swerdlow et al,
1998). Moreover, although H. pylori infects men and women about
equally and is strongly associated with duodenal ulceration, gastric
cancer is twice as common in men and may be inversely associated
with duodenal ulceration (Howson et al, 1986; Hansson et al,
1996). Clearly, if H. pylori is a cause of gastric cancer, there must
be some other major cause(s) of the disease.
To assess the role of the infection in gastric cancer more
precisely would require larger studies than hitherto, especially in
socially homogenous populations in which residual confounders
are at a minimum. Larger studies of early-onset cases (Kikuchi et
al, 1995), or of H. pylori subtypes (e.g. cytotoxin-positive strains)
(Blaser et al, 1995), or of cases with certain types of tumours (e.g.
distal gastric cancers) (Parsonnet et al, 1991), may yield stronger
relative risks, but previously reported studies in such subgroups
have been based on small numbers and liable to biases. Moreover,
some previous studies may have underestimated the role of H.
pylori infection in gastric cancer, particularly those in developing
countries that tested for antigens from Western populations (since
the prevalence of H. pylori antigens can vary substantially
between regions), and those that failed to exclude cancers reported
in the first few years of follow-up (since disease itself may render
some cases seronegative). Larger and better epidemiological
studies may require collaborative efforts to achieve appropriate
sample sizes and might benefit from the testing of hypotheses
about other infective agents in gastric cancer as well (e.g. the
Epstein–Barr virus, the genome of which is present in some gastric
cancers) (Hsieh et al, 1998). More detailed combined analyses of
the existing data on H. pylori, perhaps based on individual partici-
pant data from each of the prospective studies, could help to allow
more complete adjustment for other risk factors and to assess
associations in particular subgroups.
Unlike several other persistent infective agents that cause > 20-
fold relative risks for particular cancers (Danesh et al, 1997b), the
available evidence suggests that H. pylori is a comparatively
moderate risk factor for gastric cancer (Table 1). But, if even a
causal twofold increased risk could be confirmed, it would suggest
an effect that would be large enough to be of some practical rele-
vance, as H. pylori would then be responsible for about one-
quarter of all gastric cancers, or about 250 000 such deaths
worldwide each year (Murray and Lopez, 1997). This relatively
large attributable risk derives from the high prevalence of H.
pylori, which is found in the stomachs of about one-third of the
adults in developed countries (where it has been decreasing in
prevalence) and about two-thirds of the adults in developing
countries (Goodwin et al, 1997).
The current trials of anti-bacterial interventions in gastric cancer
prevention may well be inadequate to assess reliably any such
moderate effects. Five randomized trials of H. pylori eradication in
the prevention of gastric cancer are in progress worldwide, and
they aim collectively to randomize about 25 000 H. pylori
seropositive individuals by the year 2005, with a weighted mean
age at entry of about 50 and weighted mean follow-up of about 10
years (Forman, 1998). Two-thirds are to be recruited in Western
European countries where the incidence of gastric cancer is very
low until old age, and one-third in China and Japan.
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Correspondence to: J DaneshHowever, even if H. pylori eradication can reduce the eventual
incidence of gastric cancer by 25%, some future combined
analysis of all these trials currently in progress might well provide
a false negative result. This is suggested by analogy with smoking
cessation, which takes many years to produce a large proportional
reduction in lung cancer. Smoking cessation at age 60 produces a
reduction of less than 50% in lung cancer mortality during the first
decade after stopping, but produces a reduction of more than 50%
during the second decade (Halpern et al, 1993). If, by analogy, the
reductions in gastric cancer during the first and second decades
after allocation to H. pylori eradication are taken to be 25% and
50%, respectively, then a trial in the UK of  H. pylori eradication at
age 60 might have to randomize at least 100 000 individuals with
at least 1 decade of follow-up to achieve statistically reliable
results. Indeed, an even larger number might be needed if there is
a delay of some years before benefits emerge, if antibiotic treat-
ments become more widely used for ‘non-ulcer dyspepsia’ or if
gastric cancer rates fall more steeply than anticipated (Danesh et
al, 1996).
Recruitment of such a large total number of individuals for a
gastric prevention trial in one or more studies might be feasible,
but only with simplified study designs. This might involve, for
example, recruitment at a single visit, at which individuals are
randomized irrespective of antibody status (although a blood
sample should be stored for future testing) and then followed up to
ascertain cases of cancer and causes of death. Such a blanket
strategy might even have logistical and scientific advantages to
only recruiting the elderly in the UK, seropositive for H. pylori
antibodies. For example, storing baseline blood samples for future
testing could allow use of any improved assay methods available
only at the end of the trial (including novel techniques to identify
different bacterial subtypes). Moreover, given that individuals in
late middle-age are much more likely to develop gastric cancer
within 10–20 years of randomization than younger people, an effi-
cient research strategy might involve ‘factorial’ designs, where
bacterial eradication regimens are introduced into existing trials of
unrelated interventions among individuals of appropriate age
already monitored for long-term follow-up (e.g. participants in
vascular disease prevention trials). As effective vaccines against
H. pylori are not available (Michetti et al, 1996), perhaps some
trials should also collect information on the overall risks (Blaser,
1997), costs (Parsonnet et al, 1996; Sonnenberg and Inadomi,
1998) and possible benefits (Danesh et al, 1997a) of a short course
of antibiotic treatment.
The launch of some such mega-trials may well be justified, for it
is difficult to see how important clinical questions (e.g. ‘Does
killing H. pylori in middle-aged adults reduce the eventual inci-
dence of gastric cancer?’) and health policy questions (e.g. ‘What
are the overall risks and benefits for the population of widespread
H. pylori eradication?’) can be reliably answered without them.
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Table 1 Examples of common persistent infective agents associated with cancers
Year Infective Associated Approximate relative risk
identified agent cancer (infected vs uninfected)
1965 Hepatitis B virus Liver cancer > 50
1983 Helicobacter pylori Gastric adenocarcinoma 2.5
1983 Human papillomavirus Cervical cancer 20
(mainly types 16 and 18)
1994 Human herpesvirus-8 Kaposi’s sarcoma >50
Figure 1 Risk ratios in prospective seroepidemiological studies of H. pylori and gastric cancer. Black squares are proportional to the number of cases, with
horizontal lines representing confidence intervals. Degree of adjustment denoted as + for age and sex only; ++ these and smoking; +++ these and markers of
poverty; ++++ these and dietary information. See Danesh (1998) for details. *Updated by Wald et al (1997)
0.25 0.5 1248
Risk ratio and confidence interval
(seropositivity in cases: controls)
Webb et al (1996) China 87   ++++
Aromaa et al (1996) Finland 86   ++++
Lin et al (1995) Taiwan 29   ++++
Forman et al(1991)* UK 56   +++
Parsonnet et al (1991) USA 109   ++
Hansen et al (1994) Norway 201   +
Nomura et al (1991) Hawaii 109   +
Siman et al (1997) Sweden 56   +
Watanabe et al (1997) Japan 45   +
Tulinius et al (1997) Iceland 40   +
Total 818
Source                 Location No. of cases  Degree of
   adjustment
99% or 95% limitsREFERENCES
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